LAFAYETTE, Colo. and CAMBRIDGE, Mass., Nov. 3 /PRNewswire FirstCall/ Dharmacon, Inc., the leading global supplier of innovative RNA and RNA interference (RNAi) research products, and Akceli, Inc., a cellular systems biology company, today announced a research collaboration to study the utility of combining two powerful technologies: siRNA mediated gene silencing and whole well reverse transfection. The combination of these technologies has the potential to advance high throughput cell based gene function analysis, target validation and drug discovery.
to validate both the efficacy of whole well siRNA reverse transfection and its utility for transfection optimization. Dharmacon's siRNA will also be used to validate Akceli's cancer related siRNA sequences and cell based assays.
"Dharmacon's SMART technologies reliably deliver highly functional siRNA, so we can focus our attention on optimizing our reverse transfection technology rather than worrying about siRNA design and functionality," said David M. "Combining Dharmacon's siRNA reagents with Akceli's reverse transfection technology should enable us to provide a high throughput format for the analysis of siRNA mediated gene silencing." Dharmacon will use the information obtained from the collaboration to further enhance its expertise in designing siRNA reagents that are potent and specific, and Akceli will use the results of the collaboration to advance development of its reverse transfection methodologies. The companies also hope to develop improved methods and products for transfection optimization. siRNA or DNA) into a cell to study their effect on cellular networks and pathways. In conventional transfection, scientists add a solution containing siRNA or DNA and a transfection reagent onto cells growing in a petri dish or small vessel known as a microwell, and the foreign nucleic acids are subsequently taken up by the cell. Akceli's patent pending reverse transfection technology uses a microwell surface coated with foreign siRNA or DNA and adds cells to the coated surface rather than vice versa. is the world's leading provider of innovative RNA, small interfering RNA (siRNA) and related RNA interference (RNAi) products and technologies to the life sciences industry. Founded in 1995, Dharmacon discovered and commercialized 2' ACE(R), a Adidas Cap Mens
CONTACT: Michael Deines of Dharmacon, +1 303 604 9499; or David M. of Akceli, +1 781 628 1300; or Media, Stephen Gendel of GendeLLindheimBioCom Partners, +1 212 918 4650Related News
Akceli is a cellular systems biology company using a transfected cell microarray technology to accelerate the drug discovery process. Akceli's patent pending technology reverse transfection is a broad and powerful new platform for understanding cellular pathways and networks. Made via reverse transfection, Akceli's transfected cell microarrays provide insights into the function of genes, proteins and compounds across the entire human genome and enable significant productivity gains throughout the drug discovery and development process. Key applications of the technology include selectivity testing of lead compounds on a genome wide scale and high throughput screening with 100 or more targets in parallel. Founded in 2001 by a team of scientists from MIT's Whitehead Institute for Biomedical Research, Akceli is backed by leading venture capital firms Atlas Venture and Apple Tree Partners. Akceli is headquartered in Medford, Mass.
1 And 2 Announce Research Collaboration To Combine Reverse Transfection And siRNA For High Throughput Gene Silencing
"Akceli's technology simplifies and accelerates the transfection of nucleic acids enabling a higher throughput approach to cell based studies," said Stephen A. Scaringe, Dharmacon's co chairman and chief scientific officer. "Our combined technologies have the potential to significantly expand the utility of siRNA mediated gene silencing in functional genomics and drug discovery research. In addition, the collaboration will enable siRNA potency, specificity and cross reactivity to be assessed across a wide variety of gene targets, allowing us to further refine our SMARTselection design algorithms."
Dynavax Technologies And Berna Biotech Announce CollaborationStanford University Licenses Ingenuity Pathways Analysis, Collaborates On Systems Biology Solutions
Novartis Finland, Tamro Unit Ink Distribution DealMWG Biotech AG And Quanta Biotech Ltd. To Co Develop A Complete Range Of New Generation Thermal Cyclers From Stand Alone To RT Baltimore Orioles Hat PCR
Clinical Data ManagementCustom Clinical Laboratory Workflow System From Amersham Biosciences Designed For Windber's Breast Cancer Project
Phase Forward's Integrated Software Selected By Eli Lilly and Company (LLY) As Global Standard For Nike Hat Red
Akceli's reverse transfection technology enables a high throughput process for delivering nucleic acids to mammalian cells. This approach greatly increases the speed and simplicity with which scientists can introduce foreign nucleic acids into cells and analyze the subsequent cellular effects. Dharmacon uses SMARTselection(TM) and SMARTpool(R) technologies to produce synthetic siRNA reagents guaranteed to silence target genes with a high degree of potency and specificity. Together, these powerful technologies promise to accelerate the analysis of gene function, cellular pathways and networks.
Chiron Corporation (CHIR) Grants Nonexclusive HCV License To Rigel Pharmaceuticals, Inc. (RIGL)ThermoGenesis (KOOL) And Mediware To Develop And Market First Integrated System To Enable Production And Distribution Of Cell Therapy Products
Under terms of the agreement, Dharmacon will supply specified siRNA reagents developed with its SMARTselection and SMARTpool technologies and Akceli will provide reverse transfection materials and carry out the experiments. The results of the studies conducted using the combined technologies will be used New Era Super Bowl Xlix
novel, highly productive chemical strategy for RNA synthesis. Using its core expertise in chemistry, biology, bioinformatics and production, Dharmacon has pioneered a custom siRNA design service that employs its proprietary SMARTselection(TM) algorithms for maximizing the efficiency of gene silencing, a powerful and increasingly widely used new technology based on siRNA. The company provides the most reliable and highest quality RNA oligonucleotides and other custom RNA modification options that leverage Dharmacon's proprietary chemistries. Dharmacon is based in Lafayette, Colorado.
Instem And PAI Finalize Agreement On The Purchase Of Provantis PathologyRigel Pharmaceuticals, Inc. (RIGL) Secures Hepatitis C Virus License Agreement From Chiron Corporation (CHIR)
New Era Snapbacks On Head
New Era St. Louis Blues
Jordan Hat Snapback
New York Giants Cap
Gucci Belt Pics
Hermes Belt Price Womens
Nike Cap Black Dri Fit
Adidas Hat White And Black
Gucci Belt All Black
Ferragamo Belt Pink
Jordan Cap Pics
New Era Boston Bruins
Lv Belt Womens
Nike Hat Mens
New Era Oakland Athletics